openPR Logo
Press release

GMP Biologics Market Key Players Analysis - Amgen Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca plc, Merck KGaA, Creative Diagnostics.

06-04-2025 10:36 AM CET | Health & Medicine

Press release from: Insightace Analytic Pvt Ltd.

GMP Biologics Market

GMP Biologics Market

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "GMP Biologics Market"-, By Type (Monoclonal Antibodies, Polyclonal Antibody), By Application (Hospitals, Clinics, Others), Industry Trends, and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The GMP Biologics Market is estimated to reach over USD 153.9 Bn by 2031, exhibiting a CAGR of 14.6% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2715

Good Manufacturing Practices (GMP) comprise a comprehensive framework of standards and protocols designed to ensure the safety, integrity, and quality of medicines, biologics, and medical products throughout their production. Biologics, which are derived from living organisms, interact with human metabolic processes to modulate or enhance biological functions. Examples include hormone therapies for endocrine disorders and vaccines that stimulate immune responses. Adherence to GMP is essential for minimizing contamination risks, preventing manufacturing errors, and maintaining product stability, thereby safeguarding the safety and efficacy of biologic products during their entire manufacturing lifecycle.

Owing to their derivation from living systems, biologics exhibit greater complexity compared to conventional pharmaceuticals. This complexity introduces variability driven by factors such as environmental influences, genetic heterogeneity, disease exposure, and the presence of inherent biochemical contaminants. Consequently, the manufacturing of biologics entails unique challenges that necessitate strict compliance with GMP standards to ensure product safety, quality, and consistency.

The demand for GMP-compliant manufacturing facilities is increasing in tandem with the regulatory approvals and clinical advancement of biologic products, leading to escalated production volumes. The biologics sector offers significant growth potential, especially within emerging markets characterized by developing healthcare infrastructure and substantial unmet needs for advanced biologic therapies. Industry participants are strategically focusing on these regions to enhance their market position and address the rising demand for biologic medicines. Furthermore, ongoing innovations in bioprocessing technologies are improving production efficiency and cost-effectiveness, thereby contributing to the continued expansion of the biologics manufacturing market.

List of Prominent Players in the GMP Biologics Market:
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• AbbVie Inc.
• AstraZeneca plc
• Merck KGaA
• Creative Diagnostics
• Fisher Bioservices (Thermo Fisher Scientific)
• Polpharma Biologics
• Intertek
• HemaCare
• AGC
• AstraZeneca plc
• Merck KGaA
• Sanofi
• GlaxoSmithKline plc
• Johnson & Johnson
• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Samsung Biologics Co. Ltd.
• WuXi AppTec
• Lonza Group Ltd.
• Rentschler Biopharma SE
• Boehringer Ingelheim International GmbH
• Celltrion Inc
• Catalent Inc.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-03

Market Dynamics
Drivers:
The GMP biologics market is primarily propelled by the escalating demand for biopharmaceutical products such as medicinal proteins, vaccines, and monoclonal antibodies. These biologics provide targeted and highly effective therapeutic options for a broad spectrum of medical conditions, thereby intensifying the need for stringent GMP-compliant manufacturing processes. The rising incidence of chronic diseases, including cancer, autoimmune disorders, and infectious diseases, further fuels the demand for biologic therapies. To uphold the safety and efficacy of these products, manufacturers must comply with rigorous GMP standards. Moreover, biopharmaceutical companies are increasingly expanding their global operations by establishing GMP-compliant production facilities in key international markets. This strategic expansion enables them to fulfill diverse regional regulatory requirements and enhance patient access to biologic treatments worldwide.

Challenges:
Ensuring aseptic conditions throughout the manufacturing process is essential to maintaining the quality and safety of biologic products. The intrinsic risk of contamination in biologics production necessitates strict adherence to GMP guidelines and continuous monitoring of manufacturing operations to safeguard product integrity and patient safety.

Regional Trends:
North America is anticipated to maintain its position as the largest market for GMP biologics over the forecast period. This leadership is underpinned by the presence of leading biopharmaceutical corporations, advanced manufacturing infrastructure, and strong regulatory frameworks supported by agencies such as the U.S. Food and Drug Administration (FDA). The United States, in particular, is at the forefront of innovation and investment in biologic therapies, including monoclonal antibodies and gene-based treatments. Conversely, the Asia-Pacific region is witnessing rapid market growth, driven by expanding healthcare demands, significant investments in bi otechnology, and increasing expertise in biologics manufacturing capabilities.

Recent Developments:
• In Feb 2024, Abbie established a strategic relationship with Tentarix Biotherapeutics to explore and create novel, multi-specific, conditionally active biologic candidates in immunology and oncology.
• In June 2023, Wuxi Biologics, which provides comprehensive solutions for biologics R&D and manufacturing, has declared that it can now produce more therapeutic components and pharmaceuticals at its plant in Wuppertal, Germany.
• In March 2023, Samsung Biologic, Incheon, South Korea's Samsung Biologics is undergoing planned expansion in response to increasing market demand. When the facility is completed, it is expected to have a manufacturing capacity of 180,000 L. The firm plans to invest KRW 1.9 trillion to boost the site's capacity to 784,000 L.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2715

Segmentation of GMP Biologics Market.
Global GMP Biologics Market- By Type
• Monoclonal Antibodies
• Polyclonal Antibody
Global GMP Biologics Market - By Application
• Hospitals
• Clinics
• Others
Global GMP Biologics Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/gmp-biologics-market/2715

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GMP Biologics Market Key Players Analysis - Amgen Inc., F. Hoffmann-La Roche Ltd, AbbVie Inc., AstraZeneca plc, Merck KGaA, Creative Diagnostics. here

News-ID: 4050842 • Views:

More Releases from Insightace Analytic Pvt Ltd.

4PL Logistics Market Revenue Report with Forecast to 2034
4PL Logistics Market Revenue Report with Forecast to 2034
"4PL Logistics Market" in terms of revenue was estimated to be worth $59.6 Billion in 2024 and is poised to reach $133.3 Billion by 2034, growing at a CAGR of 8.5% from 2025 to 2034 according to a new report by InsightAce Analytic. Get Free Sample Report @ https://www.insightaceanalytic.com/request-sample/1609 Latest Drivers Restraint and Opportunities Market Snapshot: Key factors influencing the global 4PL Logistics Market are: • Rapid growth of automotive the
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to 2034
Heavy-Duty Autonomous Vehicle Market Exclusive Trends Analysis with Forecast to …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Heavy-Duty Autonomous Vehicle Market- (By Application (Logistics, Public Transportation, Construction and Mining, Others), By Propulsion Type (Internal Combustion Engine Vehicles, Electric Vehicles), By Vehicle Type (Heavy Trucks, Heavy Buses, Roboshuttles), By Level of Autonomy (Fully Autonomous Vehicles, Semi-Autonomous Vehicles), By Sensor Type (LiDAR, RADAR, Camera, Others)) Trends, Industry Competition Analysis, Revenue and Forecast To 2034." According
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
E-Commerce Logistics Market Exclusive Report with Detailed Study Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-Commerce Logistics Market Size, Share & Trends Analysis Report By Service Type (Transportation And Warehousing) And Operational Area (International And Domestic)- Market Outlook And Industry Analysis 2034" The global e-commerce logistics market is estimated to reach over USD 5340.2 billion by 2034, exhibiting a CAGR of 26.4% during the forecast period. Request For Free Sample Pages:
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
E-bikes Market Exclusive Report on the Latest Revenue and Future Scope
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global E-bikes Market Size, Share & Trends Analysis Report By Class (Class-I, Class-II, Class-III), Speed (Up to 25km/h, 25-45 km/h), Battery Type (Lithium-ion, Lithium-ion Polymer, Lead Acid), Mode (Pedal Assist, Throttle), Component (batteries, electric motors, frames with forks, wheels, crank gears, brake systems and motor controllers) , Motor Type (hub and mid), Usage (mountain, trekking, city/urban,

All 5 Releases


More Releases for GMP

Creative Peptides Released GMP Synthesis Service
Located in Shirley, New York, the world’s leading peptide supplier Creative Peptides announced the launch of its GMP synthesis (https://www.creative-peptides.com/services/custom-gmp-peptide-synthesis-services.html ) business on August 29, 2018. Now this company is focused on the development and GMP manufacturing of pharmaceutical grade peptides. As the demand of pharmaceutical market continues to grow, more and more pharmas and research institutions choose the CMO and CRO models to expand their businesses, which is more
Diapharm implements European GMP guidelines in China
Münster (DE), London (UK), Ningbo (CN), 20 December 2013 – Pharmaceutical service provider Diapharm (diapharm.com) is increasing its business activities in China: Diapharm has now implemented a “European” quality management system for Neptune Pharma Ltd (www.neptunepharma.com) in their Joint Venture Partner’s factory in Ningbo, Zhejiang Province. And it has done so successfully: The veterinary medicinal product Trident 500mg/g Powder for Suspension for Fish Treatment (www.trident-50.com), is manufactured onsite under EU
ECA Foundation releases free GMP WebApp
The ECA Foundation has been providing advanced training and information services in the pharmaceutical industry and especially with regard to pharmaceutical Quality Assurance and GMP compliance for more than 10 years. Now the organisation took advantage of its extensive experience to develop a further free of charge service – the new GMP WebApp. This new GMP WebApp runs on all smartphones and tablet PCs (Apple and Android platforms) and allows users
GMP Friction Products Awarded ISO 9001:2008
Internationally Recognized Certification Measures Consistency in Process, Procedure and Quality Performance in Manufacture of Friction Materials AKRON, OH (March 23, 2011) -- GMP Friction Products, a world leader manufacturing powdered metal friction products for clutch plates and brake pads, recently received certification for ISO 9001:2008. “ISO 9001:2008 signifies we have taken the extra measure of documenting the policies and standards to ensure consistent compliance with our manufacturing processes,” said Jerry Lynch,
GMP MANUAL Volume 2 - Validation Procedures by Maas & Peither AG – GMP Publish …
GMP Publishing is launching its new GMP MANUAL Volume 2 – Validation Procedures. The compendium on validation procedures was written by Dr. Doris Borchert, Dr. Peter Bosshard, Dr. Ralph Gomez, Dr. Michael Hiob, Dr. Christine Oechslein, Max Lazar, Ulrike Reuter, Michael Schulte, Uwe Schwarzat – all international experts and key opinion leaders. They share their detailed understanding of the various aspects of the validation process in clear and comprehensive style
blue inspection body celebrates 50 GMP audits
Münster (Germany), 20 November 2009. Two years after founding the company and just 18 months after gaining the accreditation blue inspection body GmbH announced today the successful execution of its 50th GMP audit. Further audit trips to China, India, Israel and various European countries have been scheduled already, meaning that in the first quarter 2010 the 75th audit is targeted to be completed. Blue, as a privately organised inspection body,